• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

mannkind

Study finds MannKind inhaled insulin safe, effective for children

June 22, 2025 By Sean Whooley

MannKind afrezza inhaled insulin in use

New study results demonstrated the safety and efficacy of the MannKind Afrezza inhaled insulin offering for children with type 1 diabetes. Investigators presented findings from the INHALE-1 study as a symposium at the American Diabetes Association’s 85th Scientific Sessions. The data showed that inhaled insulin offers a safe and effective replacement for rapid-acting meal insulin […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations Tagged With: ADA 2025, mannkind

MannKind reports positive data for inhaled insulin for children

December 16, 2024 By Sean Whooley

MannKind afrezza inhaled insulin in use

MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children. INHALE-1 looked at Afrezza in children and adolescents between 4-17 years of age. The company expects the data to support an upcoming request for a supplemental new drug application (sNDA) meeting with the FDA. It aims to […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: mannkind

MannKind has more positive inhaled insulin data

October 3, 2024 By Sean Whooley

MannKind afrezza inhaled insulin in use

MannKind announced top-level 30-week results from its Phase 4 INHALE-3 study comparing inhaled insulin to traditional delivery methods. The Danbury, Connecticut-based company designed Afrezza, a rapid-acting inhaled human insulin, to improve glycemic control in adults with type 1 diabetes mellitus. The INHALE-3 study looks at Afrezza against usual care. Mannkind defines usual care as multiple […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured Tagged With: mannkind

The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions

June 25, 2024 By Sean Whooley

ADA 2024 Product Images Dexcom Abbott Senseonics Ascensia Insulet Tandem Medtronic Sequel

The American Diabetes Association took to Orlando, Florida, the past few days for its 84th Scientific Sessions as optimism grows over diabetes tech. Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Patient Monitoring, Pharmaceuticals, Technology Tagged With: abbott, Dexcom, embecta, Insulet, mannkind, Medtronic, Senseonics, Sequel Med Tech, Tandem Diabetes Care

MannKind’s inhaled insulin meets primary efficacy endpoint in study

June 22, 2024 By Sean Whooley

MannKind afrezza inhaled insulin in use

MannKind today announced positive 17-week results from a Phase 4 U.S. clinical study of its Afrezza inhaled insulin powder. The Danbury, Connecticut-based company designed Afrezza, a rapid-acting inhaled human insulin, to improve glycemic control in adults with type 1 diabetes mellitus. The INHALE-3 study evaluated Afrezza against usual care — defined as multiple daily injections […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: ADA 2024, mannkind

MannKind inks $61m direct offering of common stock

October 11, 2017 By Sarah Faulkner

MannKind

MannKind (NSDQ:MNKD) said today that it inked a deal with a group of unnamed investors for a registered direct offering of 10,166,600 shares of the company’s common stock for $6.00 apiece. The $61 million offering is slated to close later this week. “With this offering, we have made substantial progress in our efforts to recapitalize […]

Filed Under: Diabetes, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: mannkind, onedrop

MannKind posts mixed Q2

August 8, 2017 By Sarah Faulkner

MannKind

Shares in MannKind Corp. (NSDQ:MNKD) fell slightly this morning after the biopharmaceutical company missed earnings expectations but beat sales estimates on Wall Street with its second quarter results. The Valencia, Calif.-based company posted a net loss of -$35.4 million on sales of $2.2 million for the 3 months ended June 30, for bottom-line loss of -18% on […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: mannkind

MannKind combines inhaled insulin with One Drop’s digital diabetes tech

August 7, 2017 By Sarah Faulkner

One Drop

MannKind Corp. (NSDQ:MNKD) and One Drop said today that the group launched its A-One trial evaluating MannKind’s inhaled insulin, Afrezza, for use with One Drop’s digital diabetes management platform. The companies reported that they are enrolling people with Type II diabetes and randomizing them in two treatment arms. One group of patients will use Afrezza with […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: mannkind, onedrop

Anika names medtech veteran as new president | Personnel Moves – July 31, 2017

July 31, 2017 By Sarah Faulkner

Anika Therapeutics

Anika Therapeutics (NSDQ:ANIK) last week named medtech veteran Joseph Darling as president, taking over the role from CEO Charles Sherwood. The chief exec plans to stay in the corner office as he transitions the role of president to Darling. Previously, Darling worked as an executive in privately-held orthopedic companies. He has also held senior level executive […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AcelRx, Anika Therapeutics Inc., Catalent, mannkind, Merrimack Pharmaceuticals, oramedpharmaceuticals

Milestone Scientific appoints new CEO following FDA nod | Personnel Moves – July 13, 2017

July 13, 2017 By Sarah Faulkner

Milestone Scientific

Milestone Scientific (NYSE:MLSS) said this week that it appointed Daniel Goldberger to the company’s corner office. Leonard Osser, who previously served as CEO, is slated to remain on the board and will continue to serve as director of Milestone’s China operations. The appointment comes on the heels of the FDA’s decision to grant Milestone’s CompuFlo epidural […]

Filed Under: Drug-Device Combinations, Featured, Personnel, Pharmaceuticals, Wall Street Beat Tagged With: AstraZeneca plc, Avalon, Biogen Idec, cingulatetherapeutics, foamixpharmaceuticals, Gamida Cell, Ipsen, mannkind, milestonescientific, Novaliq GmbH, portal instruments

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS